Evidence map›Paper›PMID 42201294›Full record

ArticleJACC. Case reports2026

First-in-Human Orthotopic Transcatheter Tricuspid Valve Replacement in a Patient With a Left Ventricular Assist Device.

Connor P Craig, Payton D Kendsersky, Nicolas H Pope, Brian A Houston, Toby B Steinberg, Lucas P Witer, Ryan J Tedford, Daniel H Steinberg, Nicholas S Amoroso

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Connor P CraigDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Payton D KendserskyDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Nicolas H PopeDivision of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Brian A HoustonDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Toby B SteinbergDepartment of Anesthesia & Perioperative Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Lucas P WiterDivision of Cardiothoracic Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.
Ryan J TedfordDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Electronic address: https://twitter.com/RyanTedfordMD.
Daniel H SteinbergDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
Nicholas S AmorosoDivision of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA. Electronic address: amoroson@musc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSignificant tricuspid regurgitation (TR) is common in patients after left ventricular assist device (LVAD) implantation and is associated with an increased risk of mortality. Studies evaluating concomitant surgical tricuspid valve intervention have not consistently demonstrated benefit. FIRST-IN-HUMAN SUMMARY: We describe a first-in-human transcatheter tricuspid valve replacement (TTVR) using the Evoque system in a 46-year-old man with medically refractory, severe TR and right ventricular failure after LVAD implantation. DISCUSSION: Our case demonstrates that TTVR is a technically feasible treatment option for LVAD patients with refractory TR, in this case improving symptoms and reducing the need for chronic inotropic support. NOVELTY: To our knowledge, this is the first report of TTVR using the Evoque valve system in a patient with an LVAD. TAKE-HOME MESSAGES: Patients with severe TR after LVAD implantation have worse outcomes, but surgical tricuspid valve intervention at the time of LVAD implantation has not consistently shown benefit. TTVR platforms may represent a therapeutic alternative for patients with persistent symptomatic TR.

Indexed as

EvoqueLVADrefractory TRTTVR

Identifiers

PMID42201294
PMCPMC13350644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.